Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of LIQ865 in Healthy Males
NCT02982889Phase 1Completed
- Sponsor
- Liquidia Corporation
- Start
- Dec 2016
- Primary completion
- Mar 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LIQ865 in postoperative pain (4 arms), sponsored by Liquidia Corporation. Primary endpoint: Incidence of Treatment Emergent Adverse Events at 30 days. Started Dec 2016; status: completed.
02
Drugs
LIQ865
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02982889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982889.